
Annexon, Inc (ANNX) Stock Forecast & Price Target
Annexon, Inc (ANNX) Analyst Ratings
Bulls say
Annexon is attractive fundamentally because its differentiated, first-in-class C1q platform targets the earliest step in the classical complement pathway, creating multiple shots on goal across high-unmet-need markets in neurology, ophthalmology, and autoimmune disease. The near-term GBS catalyst looks particularly compelling: tanruprubart showed rapid functional improvement in Phase 3, FORWARD’s first 10 patients improved within days, and the company expects a BLA submission in 4Q26, while the market is concentrated at roughly 8,000 U.S. cases and around 50 key centers. In GA, ARCHER II’s 659-patient design, over-enrollment, high compliance, and enrichment strategy support a meaningful readout in 4Q26, and even using conservative assumptions the stock appears to reflect limited value for vonaprument despite its potential to add substantial long-term sales.
Bears say
Annexon is viewed negatively because its lead asset vonaprument already failed Phase 2 on the primary GA lesion-growth endpoint, and the remaining vision-preservation signal looks fragile, driven by a small subset of patients while BCVA measurement noise adds uncertainty. In Phase 3, the company is relying on a difficult setup to reach statistical significance, requiring a low response rate against an enriched sham population, while competing GA drugs from larger, better-resourced players already have commercial momentum. Financially, Annexon finished 1Q26 with $225M in cash, but it is expected to keep incurring net losses and may need additional capital before key readouts in 4Q26 and 3Q27, creating dilution risk if development disappoints.
This aggregate rating is based on analysts' research of Annexon, Inc and is not a guaranteed prediction by Public.com or investment advice.
Annexon, Inc (ANNX) Analyst Forecast & Price Prediction
Start investing in Annexon, Inc (ANNX)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Annexon, Inc (ANNX) Forecast
Annexon, Inc (ANNX) Analyst Forecast & Price Prediction
Start investing in Annexon, Inc (ANNX)
Order type
Buy in
Order amount
Est. shares
0 shares